- Home
- Automated
- List of product information
- VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION) 0.024% [SIN16214P]
VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION) 0.024% [SIN16214P]
Active ingredients: VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION) 0.024%
Last updated 26 October 2025
On this page
Product Info
VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION) 0.024%
[SIN16214P]
Product information
Active Ingredient and Strength | LATANOPROSTENE BUNOD - 0.24 MG/ML |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | BAUSCH & LOMB, INCORPORATED. - UNITED STATES |
Registration Number | SIN16214P |
Licence Holder | BAUSCH & LOMB (SINGAPORE) PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EE06 |
1 INDICATIONS
VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Pediatrics (≤ 18 years of age): No data are available in patients below 18 years old; therefore, VYZULTA is not indicated for use in pediatrics.
Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that safety and effectiveness is comparable between elderly and other adult patients.
3 DOSAGE AND ADMINISTRATION
Dosing Considerations
Do not administer VYZULTA™ more than once daily since it has been shown that more frequent administration of prostaglandin analogues may lessen the intraocular pressure lowering effect.
If VYZULTA™ is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least 5 minutes apart.
Recommended Dose and Dosage Adjustment
The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.
VYZULTA is not indicated for use in pediatrics (≤ 18 years of age).
Administration
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Contact lenses should be removed prior to administration of VYZULTA™, because this product contains Benzalkonium Chloride. Lenses may be reinserted 15 minutes following administration of VYZULTA™.
Missed Dose
If a dose is missed, treatment should continue with the next dose as normal.
2 CONTRAINDICATIONS
Latanoprostene bunod is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition and Packaging – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.